PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
EBIT growth below 50% of GNPX's 65.55%. Michael Burry would suspect deeper competitive or cost structure issues.
-2.64%
Negative operating income growth while GNPX is at 65.55%. Joel Greenblatt would press for urgent turnaround measures.
0.38%
Net income growth under 50% of GNPX's 65.55%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.04%
EPS growth under 50% of GNPX's 64.91%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
3.04%
Diluted EPS growth under 50% of GNPX's 65.11%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.54%
Slight or no buybacks while GNPX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.54%
Slight or no buyback while GNPX is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
10.47%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.65%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
Negative 10Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-37006.68%
Negative 5Y OCF/share CAGR while GNPX is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-70.29%
Negative 3Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15642.97%
Negative 10Y net income/share CAGR while GNPX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-43858.45%
Negative 5Y net income/share CAGR while GNPX is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-130.01%
Negative 3Y CAGR while GNPX is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
Equity/share CAGR of 4179.35% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1066.60%
Equity/share CAGR of 1066.60% while GNPX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Negative asset growth while GNPX invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-27.26%
We have a declining book value while GNPX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.07%
R&D growth drastically higher vs. GNPX's 12.70%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-49.28%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.